Mobile Menu
Deals & Transactions

Conyers advises Kintor Pharmaceutical Limited in connection with its HK$1 billion IPO

Conyers provided Cayman Islands and British Virgin Islands legal advice to Kintor Pharmaceutical Limited (the “Company”) in connection with its HK$1 billion initial public offering of 92,347,500 shares on the Main Board of The Stock Exchange of Hong Kong (Stock code: 9939).

The Company is a clinical-stage novel drug developer in China focused on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other androgen receptor-related, or AR-related diseases.

Partner Richard Hall and Counsel Angie Chu of Conyers’ Hong Kong office advised on the matter, working alongside Ashurst Hong Kong and Slaughter and May.

 


Richard Hall
Partner

Hong Kong   +852 2842 9530
Mobile  +852 6469 3355


Angie Chu
Counsel

Hong Kong   +852 2842 9549
Mobile  +852 6469 3385


Accolades
_

"They understood the urgency and demanding nature of the deals that we were working on - they were very responsive and commercial, and worked with us to make it happen."
- Chambers Global